Neue Testverfahren in der Präventionsstrategie des kolorektalen Karzinoms

Zusammenfassung

Zu den neuen Verfahren beim Darmkrebs-Screening zählen die immunologischen Stuhlbluttests (iFOBT), DNA-Stuhltests, Blut-/ und Serummarker sowie darüber hinaus visualisierende Verfahren wie CT-/MRT, Kolon-Kapsel und Oncoscope. Aktuell haben die immunologischen Stuhltests die besten Karten, nach Festlegung von standardisierten Qualitätskriterien in das Früherkennungsprogramm der gesetzlichen Krankenversicherung aufgenommen zu werden. Molekulare Blut- und Serummarker sind noch in der Evaluationsphase. Ihre Bestimmung und ihr Preis sind aktuell noch ein Hindernis für ein Massen-Screening. Die CT-Kolonographie hat exzellente Detektionsraten, scheidet in Deutschland aber wegen der Strahlenbelastung als Screening-Verfahren derzeit aus. Die MR-Kolonographie kommt ohne Strahlen aus, steckt aber noch in der Entwicklungsphase. Die Kolon-Kapsel hat möglicherweise das Potenzial, ein guter diagnostischer Filter zu werden. Durch diese neuen Entwicklungen lassen sich die Teilnahmeraten beim Screening wahrscheinlich nur marginal steigern. Somit sind zukünftig auch politische Strategien zu fordern, das derzeit vorliegende opportunistische Screening umzustellen.

Schlüsselwörter

kolorektales Karzinom - Karzinom-Prävention - immunologische Stuhltests - molekulare Marker

Keywords

colorectal cancer - cancer prevention - immunological fecal occult blood tests - molecular marker

• Literatur

• 1 Ahlquist DA, Taylor WR et al. The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia. Clin Gastroenterol Hepatol 2012; 10: 272-277
• 2 Allison JE, Sakoda LC, Levin T et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst 2007; 99: 1-9
• 3 Backman V, Roy HK. Light-scattering technologies for field carcinogenesis detection: a modality for endoscopic prescreening. Gastroenterology 2011; 140: 35-41
• 4 Berger BM, Ahlquist DA. Stool DNA screening for colorectal neoplasia: biological and technical basis for high detection rates. Pathology 2012; 44: 80-88
• 5 Berrington de González A, Kim KP, Knudsen AB et al. Radiation-related cancer risks from CT colonography screening: a risk-benefit analysis. AJR Am J Roentgenol 2011; 196: 816-823
• 6 Bosch LJ, Oort FA, Neerincx M et al. DNA Methylation of Phosphatase and Actin Regulator 3 Detects Colorectal Cancer in Stool and Complements FIT. Cancer Prev Res 2012; 5: 464-472
• 7 Chen LS, Yen AM, Chiu SY et al. Baseline faecal occult blood concentration as a predictor of incident colorectal neoplasia: longitudinal follow-up of a Taiwanese population-based colorectal cancer screening cohort. Lancet Oncol 2011; 12: 551-558
• 8 de Wijkerslooth TR, Bossuyt PM, Dekker E. Strategies in screening for colon carcinoma. Neth J Med 2011; 69: 112-119
• 9 Eliakim R, Yassin K, Niv Y et al. Prospective multicenter performance evaluation of the second-generation colon capsule compared with colonoscopy. Endoscopy 2009; 41: 1026-1031
• 10 Force, U.S. Preventive Services Task. Screening for colorectal cancer\: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2008; 149: 627-637
• 11 Grützmann R, Molnar B, Pilarsky C et al. Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS ONE 2008; 3: e3759
• 12 Hartmann D, Bassler B, Schilling D et al. Colorectal polyps: detection with dark-lumen MR colonography versus conventional colonoscopy. Radiology 2006; 238: 143-149
• 13 Hol L, van Leerdam ME, van Ballegooijen M et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 2010; 59: 62-68
• 14 Hundt S, Haug U, Brenner H. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Ann Intern Med 2009; 150: 162-169
• 15 Johnson CD, Chen MH, Toledano AY et al. Accuracy of CT colonography for detection of large adenomas and cancers. N Engl J Med 2008; 359: 1207-1217
• 16 Leman ES, Schoen RE, Weissfeld JL et al. Initial analyses of colon cancerspecific antigen (CCSA)-3 and CCSA-4 as colorectal cancer-associated serum markers. Cancer Res 2007; 67: 5600-5605
• 17 Li R, Liu J, Xue H et al. Diagnostic value of fecal tumor M2-pyruvate kinase for CRC screening: A systematic review and meta-analysis. Int J Cancer 2012; Jan 19. doi [Epub ahead of print]
• 18 Liebermann D. Progress and challenges in colorectal cancer screening und surveillance. Gastroenterology 2010; 138: 2115-2212
• 19 Loitsch SM, Shastri Y, Stein J. Stool test for colorectal cancer screening--it's time to move!. Clin Lab 2008; 54: 473-484
• 20 Muralidharan K, Tint MS, Chadha AK et al. Detecting colorectal cancer based on presence of methylated septin 9 DNA in plasma. J Clin Oncol 2010; 28 : e14071
• 21 Negnan J, Patnick L, von Karsa L. European guidelines for quality assurance in colorectal cancer screening and diagnosis. http://screening.iarc.fr/doc/ND3210390ENC.pdf Zugriff 24.7.2012.
• 22 Oort FA, van Turenhout ST, Coupé VM et al. Double sampling of a faecal immunochemical test is not superior to single sampling for detection of colorectal neoplasia: a colonoscopy controlled prospective cohort study. BMC Cancer 2011; 11: 434
• 23 Pickardt PJ, Choi JR, Hwang I et al. Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults. N Engl J Med 2003; 349: 2191-2200
• 24 Quintero E, Castells A, Bujanda L et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med 2012; 366: 697-706
• 25 Quintero E. Chemical or immunological tests for the detection of fecal occult blood in colorectal cancer screening?. Gastroenterol Hepatol 2009; 32: 565-576
• 26 Sambrook A, McAteer D, Yule S et al. MR colonography without bowel cleansing or water enema: a pilot study. Br J Radiol 2012; 85: 921-924
• 27 Schmiegel W et al. S3 Leitlinie „Kolorektales Karzinom“ 2004/2008. Z Gastroenterol 2009; 47: 37-54
• 28 Scholefield JH, Moss SM, Mangham CM et al. Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up. Gut 2012; 61: 1036-1040
• 29 Schoofs N, Devière J, Van Gossum A. PillCam colon capsule endoscopy compared with colonoscopy for colorectal tumor diagnosis: a prospective pilot study. Endoscopy 2006; 38: 971-977
• 30 Spada C, Hassan C, Galmiche JP et al. Colon capsule endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2012; 44: 527-536
• 31 Towler B et al. A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, hemoccult. BMJ 1998; 317: 559-565
• 32 Turzhitsky V, Radosevich AJ, Rogers JD et al. Measurement of optical scattering properties with low-coherence enhanced backscattering spectroscopy. J Biomed Opt 2011; 16: 067007
• 33 Van Gossum A, Munoz-Navas M, Fernandez-Urien I et al. Capsule endoscopy versus colonoscopy for the detection of polyps and cancer. N Engl J Med 2009; 361: 264-270
• 34 Whitlock EP, Lin JS, Liles E et al. Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2008; 149: 638-658
• 35 Wilson S, Damery S, Stocken DD et al. Serum matrix metalloproteinase 9 and colorectal neoplasia: a community-based evaluation of a potential diagnostic test. Br J Cancer 2012; 106: 1431-1438
• 36 Zhu MM, Xu XT, Nie F et al. Comparison of immunochemical and guaiac-based fecal occult blood test in screening and surveillance for advanced colorectal neoplasms: a meta-analysis. J Dig Dis 2009; 11: 148-160
• 37 Zijta FM, Bipat S, Stoker J. Magnetic resonance (MR) colonography in the detection of colorectal lesions: a systematic review of prospective studies. Eur Radiol 2010; 20: 1031-1046